| Seppo Tapani Rinne, MD | |
|
1 Medical Center Dr, Lebanon, NH 03756-0001 | |
| (603) 650-5000 | |
| Not Available |
| Full Name | Seppo Tapani Rinne |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619151503 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emerson Practice Associates, Inc | 8123188117 | 192 |
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.
The use of expandable electrodes with multiple tips in the treatment of liver tumors by radiofrequency ablation (RFA) is safe and effective, making it a useful alternative to surgery in selected patients, say researchers from the University of Brescia in Italy.
BELLUS Health announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.
Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date.
› Verified 3 days ago
| Entity Name | Evans Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912954124 PECOS PAC ID: 7416946546 Enrollment ID: O20040512000397 |
News Archive
A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.
The use of expandable electrodes with multiple tips in the treatment of liver tumors by radiofrequency ablation (RFA) is safe and effective, making it a useful alternative to surgery in selected patients, say researchers from the University of Brescia in Italy.
BELLUS Health announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.
Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date.
› Verified 3 days ago
| Entity Name | Emerson Practice Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508020199 PECOS PAC ID: 8123188117 Enrollment ID: O20081120000518 |
News Archive
A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.
The use of expandable electrodes with multiple tips in the treatment of liver tumors by radiofrequency ablation (RFA) is safe and effective, making it a useful alternative to surgery in selected patients, say researchers from the University of Brescia in Italy.
BELLUS Health announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.
Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Seppo Tapani Rinne, MD Po Box 810, Hanover, NH 03755-0810 Ph: () - | Seppo Tapani Rinne, MD 1 Medical Center Dr, Lebanon, NH 03756-0001 Ph: (603) 650-5000 |
News Archive
A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.
The use of expandable electrodes with multiple tips in the treatment of liver tumors by radiofrequency ablation (RFA) is safe and effective, making it a useful alternative to surgery in selected patients, say researchers from the University of Brescia in Italy.
BELLUS Health announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.
Lung transplantation, the therapy almost every cystic fibrosis patient (CF) considers at some point to prolong survival, rarely helps children with the disease live longer and, in fact, often increases their risk of dying, University of Utah researchers conclude in the most extensive study of the issue to date.
› Verified 3 days ago
Elias Loukas, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Section Of Hospital Medicine, Lebanon, NH 03756 Phone: 603-650-8380 | |
Dr. Michael W Winter, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Gastroenterology, Lebanon, NH 03756 Phone: 603-650-5261 | |
Hannah Elizabeth Foote Bensimhon, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Victoria Forbes, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5516 | |
Zanira Fazal, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18 Old Etna Rd, Lebanon, NH 03766 Phone: 603-650-4000 | |
Susan Si-yao Wang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth-hitchcock Medical Ctr, Department Of Medicine, Lebanon, NH 03756 Phone: 603-650-9480 | |
Mark Edward Splaine, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Section Of General Internal Medicine, Lebanon, NH 03756 Phone: 603-653-9500 |